# A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

> **NCT05584644** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 150 (actual)

## Conditions studied

- Breast Cancer
- Breast Carcinoma
- Breast Neoplasms
- Breast Tumors
- Cancer of Breast

## Interventions

- **DRUG:** Palbociclib plus hormonal treatment - first line treatment
- **DRUG:** Palbociclib plus hormonal treatment - second line treatment

## Key facts

- **NCT ID:** NCT05584644
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-24
- **Primary completion:** 2022-02-22
- **Final completion:** 2022-02-22
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2023-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05584644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05584644, "A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05584644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*